EXHIBIT 1

Case 1:23-cv-03459-TJK Document 1-1 Filed 11/16/23 Page 2 of 8

Monica C. Groat
Direct Dial: 202.637.2281
monica.groat@lw.com

LATHAM & WATKINS LLP

September 26, 2023

VIA ELECTRONIC MAIL AND FEDERAL EXPRESS

CMS FOIA Officer
Centers for Medicare & Medicaid Services
Mailstop N2-20-16
7500 Security Boulevard
Baltimore, MD 21244
FOIA Request@cms.hhs.gov

Dubai
Düsseldorf
Frankfurt

Hong Kong Houston London

Los Angeles

www.lw.com

Austin

Beijing Boston

Brussels

Chicago

Hamburg

Century City

Madrid Washington, D.C.

555 Eleventh Street, N.W., Suite 1000

Milan

Paris

Riyadh

Seoul

Shanghai

Singapore

Tel Aviv

Tokvo

San Diego

San Francisco

Silicon Valley

New York

Orange County

Tel: +1.202.637.2200 Fax: +1.202.637.2201

Washington, D.C. 20004-1304

FIRM / AFFILIATE OFFICES

Re: Freedom of Information Act Request

To Whom It May Concern:

Under the federal Freedom of Information Act ("FOIA"), 5 U.S.C. § 552, Latham & Watkins LLP ("Latham") is requesting access to the following records, including, but not limited to, emails, formal and informal policies, standard operating procedures, guidelines, internal memoranda, internal and external communications, and any other relevant material (hereinafter, "all records"):

- All records associated with the narrow exception process under which certain drugs approved under paper New Drug Applications ("NDAs") or literature-based 505(b)(2) NDAs might be classified as a noninnovator multiple source drug (also known as an "N drug"), including, but not limited to, all materials that the Centers for Medicare and Medicaid Services ("CMS") uses to inform the evaluation of narrow exception requests;
- All records associated with all applications seeking a determination from CMS that an
 applicant's drugs qualify for the narrow exception and can be classified as
 noninnovator multiple source drugs (N drugs), including but not limited to the
 applications, and all corresponding decisions from CMS regarding these narrow
 exception applications;
- All records associated with all internal communications regarding the terms
 "literature-based 505(b)(2) New Drug Applications," "literature-based 505(b)(2)
 NDAs," "paper New Drug Applications," and "paper NDAs" including but not
 limited to CMS's definition of the terms "literature-based 505(b)(2) New Drug
 Applications," "literature-based 505(b)(2) NDAs," "paper New Drug Applications,"
 and "paper NDAs"; and

September 26, 2023 Page 2

LATHAM & WATKINS LLP

- All records associated with all communications between CMS and the Food and Drug Administration ("FDA") regarding the terms "literature-based 505(b)(2) New Drug Applications," "literature-based 505(b)(2) NDAs," "paper New Drug Applications," and "paper NDAs," including but not limited to:
 - o Communications between CMS and FDA regarding the definitions of the terms "literature-based 505(b)(2) New Drug Applications," "literature-based 505(b)(2) NDAs," "paper New Drug Applications," and "paper NDAs"; and
 - Communications between CMS and FDA regarding the narrow exception process and/or narrow exception applications.

In order to determine the status of this request for the purpose of assessing fees, Latham is a private business and is seeking information for use in the company's business. If this request is denied, in whole or in part, please justify all denials by reference to specific exemptions under FOIA. Please also release all segregable portions of otherwise exempt material. Latham will pay all necessary fees.


Latham requests that the information Latham is seeking be provided in electronic format. If you have any questions about handling this request, please contact Monica Groat at 202-637-2281 or monica.groat@lw.com.

Sincerely,

Monica C. Groat

Monica C. Groat

Of Latham & Watkins LLP







MENU

Thank you for visiting FOIA.gov, the government's central website for FOIA. We'll continue to make improvements to the site and look forward to your input. Please submit feedback to National.FOIAPortal@usdoj.gov.

Submission ID: 875296

Success!

Your FOIA request has been created and is being sent to the Center for Medicare and Medicaid Services.

You'll hear back from the agency confirming receipt in the coming weeks using the contact information you provided. If you have questions about your request, feel free to reach out to the agency FOIA personnel using the information provided below.

Contact the agency

Hugh Gilmore, FOIA Officer

410-786-5353

hugh.gilmore@cms.hhs.gov

FOIA Requester Service Center

410-786-5353

Joseph Tripline, FOIA Public Liaison

410-786-5353

joseph.tripline@cms.hhs.gov

9/26/23, 4:01 PM

Hugh Gilmore, FOIA Officer, North Building, Room C5-11-06 7500 Security Boulevard Baltimore, MD 21244

FOIA_Request@cms.hhs.gov

Request summary

Request submitted on September 26, 2023.

The confirmation ID for your request is 875296.



The confirmation ID is only for identifying your request on FOIA.gov and acts as a receipt to show that you submitted a request using FOIA.gov. This number does not replace the information you'll receive from the agency to track your request. In case there is an issue submitting your request to the agency you selected, you can use this number to help.

Contact information

Name

Monica Groat

Mailing address

555 11th St NW Suite 1000 Washington, DC 20004 United States

Phone number

202-637-2281

Company/organization

Latham & Watkins

Email

monica.groat@lw.com

Your request

The following records, including, but not limited to, emails, formal and informal policies, standard operating procedures, guidelines, internal memoranda, internal and external communications, and any other relevant material (hereinafter, "all records"): • All records associated with the narrow exception process under which certain drugs approved under paper New Drug Applications ("NDAs") or literature-based 505(b)(2) NDAs might be classified as a noninnovator multiple source drug (also known as an "N drug"), including, but not limited to, all materials that the Centers for Medicare and Medicaid Services ("CMS") uses to inform the evaluation of narrow exception requests; • All records associated with all applications seeking a determination from CMS that an applicant's drugs qualify for the narrow exception and can be classified as noninnovator multiple source drugs (N drugs), including but not limited to the applications, and all corresponding decisions from CMS regarding these narrow exception applications; • All records associated with all internal communications regarding the terms "literaturebased 505(b)(2) New Drug Applications," "literature-based 505(b)(2) NDAs," "paper New Drug Applications," and "paper NDAs" including but not limited to CMS's definition of the terms "literature-based 505(b)(2) New Drug Applications," "literature-based 505(b) (2) NDAs," "paper New Drug Applications," and "paper NDAs"; and All records associated with all communications between CMS and the Food and Drug Administration ("FDA") regarding the terms "literature-based 505(b)(2) New Drug Applications," "literaturebased 505(b)(2) NDAs," "paper New Drug Applications," and "paper NDAs," including but not limited to: o Communications between CMS and FDA regarding the definitions of the terms "literature-based 505(b)(2) New Drug Applications," "literature-based 505(b)(2) NDAs," "paper New Drug Applications," and "paper NDAs"; and o Communications between CMS and FDA regarding the narrow exception process and/or narrow exception applications.

Additional information

Sandoz - FOIA Request CMS (9.26.23).pdf

Fees

What type of requester are you?

commercial

Fee waiver

no

The amount of money you're willing to pay in fees, if any

10000

Request expedited processing

Expedited processing

no



CONTACT

Office of Information Policy (OIP)
U.S. Department of Justice
441 G St, NW, 6th Floor
Washington, DC 20530
E-mail: National.FOIAPortal@usdoj.gov

Hero image credit 🔼 CC3.0

FREQUENTLY ASKED QUESTIONS

DEVELOPER RESOURCES

AGENCY API SPEC

FOIA CONTACT DOWNLOAD

FOIA DATASET DOWNLOAD

ACCESSIBILITY

PRIVACY POLICY

POLICIES & DISCLAIMERS

JUSTICE.GOV

USA.GOV ☐